Get the Stockscreener App
0.228
0.87%
-0.002
Theriva Biologics Inc stock is traded at $0.228, with a volume of 541.96K.
It is down -0.87% in the last 24 hours and down -5.04% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.23
Open:
$0.235
24h Volume:
541.96K
Relative Volume:
0.09
Market Cap:
$10.46M
Revenue:
-
Net Income/Loss:
$-21.46M
P/E Ratio:
-0.09
EPS:
-2.5324
Net Cash Flow:
$-14.40M
1W Performance:
+3.26%
1M Performance:
-5.04%
6M Performance:
+25.27%
1Y Performance:
-47.59%
1-Day Range:
$0.22
$0.2379
1-Week Range:
$0.22
$0.2543
52-Week Range:
$0.1628
$0.8632
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.228 | 11.01M | 0 | -21.46M | -14.40M | -2.5324 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Theriva Biologics Inc Stock (TOVX) Latest News
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView
Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative
Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView
Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan
Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Yahoo Finance UK
TOVX Stock Price and Chart — AMEX:TOVX - TradingView
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan
Theriva’s Six-Patient Cancer Trial Is Designed to Test Repeat Virus Dosing - Stock Titan
Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks
Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan
Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView
TOVX|Theriva Biologics Inc|Price:0.222|Chg%:+0.012 - TradingKey
Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theriva Biologics Inc (TOVX) Cash Flow - TradingKey
TOVX|Theriva Biologics Inc|Price:0.214|Chg%:-0.009 - TradingKey
Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theriva Biologics, Inc. Revenue Breakdown – BOATS:TOVX - TradingView
Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TOVX|Theriva Biologics Inc|Price:0.223|Chg%:-0.001 - TradingKey
Theriva Biologics (TOVX) Proxy Filing Summary - Quartr
Theriva Biologics (TOVX) Slides 5% as Selling Pressure Mounts Near Key SupportMomentum Stock Picks - dars.gov.et
Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support LevelsAI Trade Signals - dars.gov.et
symbol__ Stock Quote Price and Forecast - CNN
Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus
Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - Moomoo
Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks
Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan
Theriva Biologics receives approval to start VIRAGE2 cancer trial By Investing.com - Investing.com Canada
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - The Manila Times
Theriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trial - Stock Titan
Theriva Biologics (TOVX) Holds Steady Near Support After Modest GainOrder Block - DonanımHaber
Form DEF 14A THERIVA BIOLOGICS For: 29 June By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) puts large share and warrant proposals to vote - Stock Titan
Enterprise value to EBIT forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to book forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Enterprise value to EBIT forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to EBITDA forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to revenue forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Price to sales forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to earnings forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Cap:
|
Volume (24h):